Physician profile
Timothy Fleming
NPI 1043315062
$2,193.37
in general payments reported to CMS, 2019-2025
20 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.18 · 2022: $11.77 · 2023: $270 · 2024: $147 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $539.57 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $461.00 | 2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $179.08 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $162.66 | 2025 | Rexulti |
| Abbott Laboratories | $140.11 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Teva Pharmaceuticals USA, INC. | $129.71 | 2023 | Uzedy |
| Lilly USA, LLC | $108.67 | 2021-2025 | Kisunla, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $67.30 | 2024 | Voquezna |
| Abbvie INC. | $67.22 | 2025 | |
| Exact Sciences Corporation | $50.71 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $44.28 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $42.06 | 2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $35.21 | 2025 | |
| Amgen INC. | $34.40 | 2025 | Krystexxa, Otezla |
| Genentech USA, INC. | $34.26 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.78 | 2024 | Auvelity |
| Davol INC. | $21.51 | 2025 | Phasix Mesh |
| Corcept Therapeutics | $19.32 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $17.48 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.04 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.